DC67602 · Updated 27 October 2026
ILB-3132 Product Datasheet
Print / Save PDF DC67602 is catalogued as ILB-3132. The displayed chemical structure matches the patent compound E12LA6B6O3, which was evaluated in reporter-mRNA delivery and an OVA-mRNA tumor-model study. The reviewed primary sources do not independently establish that E12LA6B6O3 is the proprietary clinical lipid called ILB-3132.
CAS No. Not available Chemical Name ILB-3132（E12LA6B603) Synonyms ILB3132， ILB 3132 SMILES CCCCCCCCCCC(COC(=O)CCCCC)OC(=O)CCCCCN(CCCO)CCCCCC(=O)OC(CCCCCCCCCC)COC(=O)CCCCC Formula C51H97NO9 M.Wt 868.335 Purity >95% by ELSD-HPLC Storage Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light. Shipping condition Ships from Shanghai. Pure lipid is stable during ice-pack transport. Publication Fang W, Qin H, Xu Y, Wu Q. Amino lipid, and lipid nanoparticles and use thereof. WO2024198497A1, published October 3, 2024. Example 2; Examples 36–40; Tables 1–5; Figures 2–3. WO2024198497A9, corrected publication September 18, 2025. Corrected searchable text reviewed; figure and table identity not fully reverified. MagicRNA. ASGCT 28th Annual Meeting announcement, April 30, 2025. Sponsor-level naming of ILB-3132; not a disclosed molecular structure. Wang Q, et al. In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus. New England Journal of Medicine. 2025;393:1542–1544. DOI: 10.1056/NEJMc2509522. Background platform reference only.
Research evidence Read detailed Formulation & Performance
Specifications are catalog specifications, not batch test results.
